Effect of bisphosphonate administration on the excretion of stress hormones in tail-suspended rats.
We demonstrated that administration of a bisphosphonate, YH529, prevents the development of disuse atrophy of the hind limbs induced by tail-suspension in rats. Since tail suspension is accompanied by an increase in the secretion of stress hormones, we studied whether administration of bisphosphonate affects the secretion of stress hormones during that procedure. Tail suspension was carried out in a metabolic cage by connecting a wire inserted through tail bone to the ceiling of the cage. The control rat received the same treatment but was not suspended. YH529 or a vehicle (PBS=phosphate buffered saline) was administered daily starting 3 days before the commencement of tail suspension. Urine samples were collected before the wire was inserted (day 0), on the day of insertion (day 1) and 3, 5 and 7 days after. In the control rats receiving PBS, urinary excretion of corticosterone and epinephrine did not change throughout the 7-day experimental period. In the control rats receiving YH529, urinary excretion of corticosterone increased significantly on the day of tail-piercing and wiring but then returned to the prior level. This increase was not observed in the control group receiving PBS. In the tail suspended rats, excretion of corticosterone and epinephrine increased significantly in both PBS and YH529 groups, the highest level being observed on the first day of tail suspension. Although statistically not significant, corticosterone excretion on day 1 of tail suspension was higher in the YH529 groups than that in the PBS group. It is thus suggested that administration of YH529 causes an augmented response to stress load.
Ohmori
S
S
Department of Endocrinology and Metabolism, Division of Molecular Cellular Adaptation, Research Institute of Environmental Medicine, Nagoya University, Nagoya, Japan.
Kurokouchi
K
K
Kanda
K
K
Kawano
S
S
Ito
T
T
Izumi
R
R
Yasukawa
K
K
Inazu
M
M
Murata
Y
Y
Seo
H
H
D000818:Animals; D018488:Bone Demineralization, Pathologic / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control*; D003345:Corticosterone / Q000378:metabolism* / Q000652:urine; D004164:Diphosphonates / Q000494:pharmacology*; D004837:Epinephrine / Q000378:metabolism* / Q000652:urine; D019417:Hindlimb Suspension / Q000009:adverse effects*; D007093:Imidazoles / Q000494:pharmacology*; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D012965:Sodium Chloride / Q000494:pharmacology; D013312:Stress, Physiological / Q000209:etiology / Q000378:metabolism*; D013997:Time Factors; D018474:Weightlessness Simulation
D004164:Diphosphonates; D007093:Imidazoles; C087958:YM 529; D012965:Sodium Chloride; D003345:Corticosterone; D004837:Epinephrine